Metrics as of 10/16/2026, 09:40 PM (Berlin time), refresh in progress.
Spyre Therapeutics Stock
Spyre Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Cameron Turtle
- Employees
- 125
- Market cap
- $7.4 B
- IPO
- 07/04/2016
Spyre Therapeutics, Inc. is a U.S.-based healthcare/biotechnology company headquartered in Waltham, Massachusetts. Trading under the ticker symbol SYRE, the biopharmaceutical firm focuses on the preclinical development of innovative treatments for chronic inflammatory bowel diseases such as ulcerative colitis and…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Spyre Therapeutics stock: price history
1D
-0.1%
1W
-6.6%
1M
-12.2%
6M
+9.6%
YTD
+144.4%
1Y
+259.9%
2Y
+147.3%
5Y
-60.9%
10Y
-52.6%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~22% weaker price swings than usual
Spyre Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Spyre Therapeutics Inc. is a preclinical-stage biotechnology company specializing in developing innovative treatments for chronic inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. The primary business model consists of research and development of human monoclonal antibodies, including therapeutics targeting the α4β7 integrin or tumor necrosis factor-like ligand 1A (TL1A), as well as various combination therapies with different mechanisms of action. The company employs both single antibody and dual antibody therapeutics in its pipeline portfolio. As the company is currently in preclinical evaluation, no revenues from product sales or licensing are being realized at this time.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Spyre Therapeutics
Analyst assessment of Spyre Therapeutics
PRICE TARGET LOW
US$107.00
CONSENSUS
US$119.89
MEDIAN
US$120.00
PRICE TARGET HIGH
US$130.00
0
STRONG BUY
12
BUY
1
HOLD
0
SELL
0
STRONG SELL
13
TOTAL · Buy
As of: 01/10/2026
Spyre Therapeutics stock metrics
P/E
-41.09
P/B
6.16
EV/EBITDA
-38.98
RETURN ON EQUITY
-3.3%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
89.3%
FLOAT SHARES
82,411,607
AVG. DAILY VOLUME (30D)
1,423,717
Insider transactions (SEC)
Turtle Cameron
King-Jones Heidy
King-Jones Heidy
King-Jones Heidy
King-Jones Heidy
Attention
Price since yesterday: -0.1%
Search (Google Trends)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Spyre Therapeutics stock
What does Spyre Therapeutics do?
Spyre Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Cameron Turtle, the company employs around 125 people.
The IPO was on 07/04/2016; the stock trades on NASDAQ under the ticker SYRE.
What do analysts say about Spyre Therapeutics stock?
13 analysts rate the stock, the consensus is Buy (as of 01/10/2026).
The average price target is US$119.89, ranging from US$107.00 to US$130.00, with a median of US$120.00.
This is an external assessment, not a statement by Market Jury.
When does Spyre Therapeutics report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly -22% stronger than usual.
Does Spyre Therapeutics pay a dividend?
No, Spyre Therapeutics currently does not pay a dividend.
Which stocks are comparable to Spyre Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Spyre Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Spyre Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.